Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma

Molecular Imaging and Biology

Volumn 6, Issue 6, 2004, Pages 411-416

  Allen Auerbach, Martin ^a   Quon, Andrew ^a   Weber, Wolfgang A ^a   Obrzut, Sebastian ^a   Crawford, Tyler ^a   Silverman, Daniel H S ^a   Ratib, Osman ^a   Phelps, Michael E ^a   Czernin, Johannes ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FDG PET; Lymphoma; PET CT; Software fusion; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CHI SQUARE TEST; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 10244221207     PISSN: 15361632     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mibio.2004.08.004     Document Type: Article

References (29)

1. J.E. Filmont J. Czernin C. Yap et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation Chest 124 2003 608-613
2. K. Spaepen S. Stoobants P. Dupont et al. Prognostic value of positron emission tomoraphy with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J. Clin. Oncol. 19 2001 414-419
3. G. Jerusalem V. Warland F. Najjar et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma Nucl. Med. Commun. 20 1999 13-20
4. C.K. Hoh J. Glaspy P. Rosen et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma J. Nucl. Med. 38 1997 343-348
5. F. Moog M. Bangerter C.G. Diederichs et al. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging Radiology 203 1997 795-800
6. K. Stumpe M. Urbinelli H. Steinert et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography Eur. J. Nucl. Med. 25 1998 721-728
7. F. Moog M. Bangerter C.G. Diederichs et al. Extranodal malignant lymphoma: Detection with FDG PET versus CT Radiology 206 1998 475-481
8. I. Buchmann M. Reinhardt K. Elsner et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial Cancer 91 2001 889-899
9. S.S. Gambhir J. Czernin J. Schwimmer et al. A tabulated summary of the FDG PET literature J. Nucl. Med. 42 2001 1S-93S
10. D.W. Townsend S.R. Cherry Combining anatomy and function: The path to true image fusion Eur. Radiol. 11 2001 1968-1974
11. L.S. Freudenberg G. Antoch P. Schutt et al. FDG-PET/CT in re-staging of patients with lyphoma Eur. J. Nucl. Med. Mol. Imaging 31 2004 325-329
12. B.S. Halpern M. Dahlbom A. Quon et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability J. Nucl. Med. 45 2004 797-801
13. T. Beyer D.W. Townsend T. Brun et al. A combined PET/CT scanner for clinical oncology J. Nucl. Med. 41 2000 1369-1379
14. P.E. Kinahan D.W. Townsend T. Beyer D. Sashin Attenuation correction for a combined 3D PET/CT scanner Med. Phys. 25 1998 2046-2053
15. A. Roche G. Malandain N. Ayache Unifying maximum likelihood approaches in medical image registration Int. J. Imaging Syst. Technol. 11 2000 71-80
16. P.J. Slomka Software approach to merging molecular with anatomic information J. Nucl. Med. 45 2004 36S-45S
17. P.J. Slomka D. Dey C. Przetak et al. Automated 3-dimensional registration of stand-alone (18)F-FDG whole-body PET with CT J. Nucl. Med. 44 2003 1156-1167
18. W.G. Finn S.H. Kroft New classifications for non-Hodgkin's lymphoma Cancer Treat. Res. 99 1999 1-26
19. P. Zinzani M. Magagnoli F. Chierichetti et al. The role of positron emission tomography (PET) in the management of lymphoma patients Ann. Oncol. 10 1999 1181-1184
20. H.W. Yeung R.K. Grewal M. Gonen et al. Patterns of (18)F-FDG uptake in adipose tissue and muscle: A potential source of false-positives for PET J. Nucl. Med. 44 2003 1789-1796
21. J.B. Bomanji R. Syed C. Brock et al. Challenging cases and diagnostic dilemmas: Case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin's disease J. Clin. Oncol. 20 2002 3347-3349
22. C. Cohade M. Osman H.K. Pannu et al. Uptake in supraclavicular area fat ("USA-Fat";): Description on 18F-FDG PET/CT J. Nucl. Med. 44 2003 170-176
23. A. Buck G. Halter H. Schirrmeister et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG J. Nucl. Med. 44 2003 1432-1434
24. I.R. Kamel C. Cohade E. Neyman et al. Incremental value of CT in PET/CT of patients with colorectal carcinoma Abdom. Imag. 2004 29
25. F. Cabanillas F.B. Hagemeister P. McLaughlin et al. Results of MIME salvage regimen for recurrent or refractory lymphoma J. Clin. Oncol. 5 1987 407-412
26. R. Elstrom L. Guan G. Baker et al. Utility of FDG-PET scanning in lymphoma by WHO classification Blood 101 2003 3875-3876
27. L.E. Albertyn Rationales for the use of intravenous contrast medium in computed tomography Australas. Radiol. 33 1989 29-33
28. H. Schöder J. Meta C. Yap et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma J. Nucl. Med. 42 2001 1139-1143
29. S. Partridge A. Timothy M.J. O'Doherty et al. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution Ann. Oncol. 11 2000 1273-1279